Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVLONASDAQ:GNCAOTCMKTS:MSLPOTCMKTS:SNNAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVLOEvelo Biosciences$0.00-20.0%$0.00$0.00▼$0.06$8K0.7710,980 shs4,282 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/AMSLPMusclePharm$0.00$0.00▼$0.00$7K-0.0726,442 shsN/ASNNAQSienna Biopharmaceuticals$0.00$0.00▼$0.00$2K1.2160 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVLOEvelo Biosciences0.00%-20.00%-20.00%-84.00%-33.33%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%+150.00%MSLPMusclePharm0.00%0.00%0.00%0.00%-83.33%SNNAQSienna Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMSLPMusclePharmN/AN/AN/AN/AN/AN/AN/AN/ASNNAQSienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVLOEvelo Biosciences 0.00N/AN/AN/AGNCAGenocea Biosciences 0.00N/AN/AN/AMSLPMusclePharm 0.00N/AN/AN/ASNNAQSienna Biopharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AGNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00MSLPMusclePharm$50.04M0.00N/AN/A($0.94) per share0.00SNNAQSienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A5/30/2025 (Estimated)GNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/AMSLPMusclePharm-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/ASNNAQSienna BiopharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVLOEvelo BiosciencesN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AMSLPMusclePharmN/AN/AN/AN/AN/ASNNAQSienna BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVLOEvelo BiosciencesN/AN/AN/AGNCAGenocea Biosciences0.241.351.35MSLPMusclePharmN/A0.250.23SNNAQSienna BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVLOEvelo Biosciences0.31%GNCAGenocea Biosciences0.64%MSLPMusclePharm15.49%SNNAQSienna BiopharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEVLOEvelo Biosciences1.02%GNCAGenocea Biosciences1.61%MSLPMusclePharm60.70%SNNAQSienna Biopharmaceuticals27.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableMSLPMusclePharm2033.39 million13.12 millionNot OptionableSNNAQSienna Biopharmaceuticals6022.93 millionN/ANot OptionableSNNAQ, EVLO, MSLP, and GNCA HeadlinesRecent News About These CompaniesSienna Announces Change of timing to Third Quarter 2024 Conference CallNovember 4, 2024 | markets.businessinsider.comWhat is Sienna Miller's Net Worth?October 31, 2024 | celebritynetworth.comHollyoaks rconfirms Vicky and Sienna alliance in Ethan death mysteryOctober 14, 2024 | aol.comHollyoaks confirms Vicky drama ahead of Ethan and Sienna’s weddingSeptember 28, 2024 | digitalspy.comSienna Miller just made a serious case for autumn pastels in a gorgeously boho outfit with astonishingly chic sunglassesSeptember 27, 2024 | womanandhome.comThe fashion house Kamala Harris and Sienna Miller have in commonSeptember 26, 2024 | msn.comBoho's back! Sienna Miller and Kate Middleton set autumn's fashion mood (think: ruffle dresses and leathers)September 26, 2024 | msn.com'I found the perfect Sienna Miller-inspired boho style dress in M&S this weekend'September 25, 2024 | mirror.co.ukSienna Almost Doubles Acreage of Case Lake West Cesium and Spodumene Pegmatite Project in OntarioSeptember 25, 2024 | msn.comHollyoaks spoiler: Sienna and Ethan face oppositionSeptember 24, 2024 | digitalspy.comHollyoaks spoilers: BIG DAY! Sienna Blake and Ethan have exciting wedding plans!September 24, 2024 | msn.comHollyoaks star Anna Passey issues huge warning over Sienna story: ‘You won’t know what to believe’September 23, 2024 | metro.co.uk2025 Toyota Sienna Adds New Interior Tech and Bumps PriceSeptember 20, 2024 | autoweek.comWhy Princess Beatrice's daughter Sienna didn't receive tributes on 3rd birthday from family membersSeptember 19, 2024 | msn.comPrincess Beatrice daughter Sienna’s noble title revealedSeptember 19, 2024 | thenews.com.pkToyota Sienna gets millimetre wave radar rear seat reminderSeptember 18, 2024 | just-auto.comThe Refreshed 2025 Toyota Sienna Literally SucksSeptember 18, 2024 | msn.comPrincess Beatrice broke special family tradition with daughter Sienna's nameSeptember 18, 2024 | mirror.co.ukSienna Miller is My Autumn Style Muse––These are the 6 Classic Items She Wears on RepeatSeptember 13, 2024 | msn.comSienna Miller Talks Nurturing New Talent Alongside Cate Blanchett With Bull-Jumping Short ‘Marion’September 13, 2024 | hollywoodreporter.comMedia Sentiment Over TimeSNNAQ, EVLO, MSLP, and GNCA Company DescriptionsEvelo Biosciences NASDAQ:EVLO$0.0004 0.00 (-20.00%) As of 05/23/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.MusclePharm OTCMKTS:MSLPMusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.Sienna Biopharmaceuticals OTCMKTS:SNNAQSienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
